AtriCure, Inc. vs Pfizer, Inc. — Stock Comparison
Q·Score Breakdown
6.7
Neutral
Overall
6.5
Neutral
Quality
Health
Growth
Valuation
Sentiment
ATRC
Clean balance sheet with low leverage (0.2× debt-to-equity).
⚠ currently unprofitable (-2% margin).
PFE
Strong profitability with 12% net profit margins.
⚠ analyst sentiment is cautious.
Analyst Consensus
BUY
Target $46.75 (+61.1%)
8 analysts
HOLD
Target $29.00 (+10.2%)
27 analysts
Fundamentals
ATRC
PFE
—
Trailing P/E
19.4×
78.5×
Forward P/E
9.4×
-2.1%
Profit Margin
12.4%
75.0%
Gross Margin
75.8%
-2.4%
ROE
8.9%
13.1%
Revenue Growth
-1.2%
—
Earnings Growth
—
1.43
Beta
0.39
—
Price / Book
—
$1.5B
Market Cap
$149.8B
$27 – $43
52-Week Range
$22 – $29
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →